Research and development daily adamumumab, the first similar drug to be listed in China, won the title of baiaotai!

Gilead science two new HIV drugs show long-term efficacy; the first adalimumab biological similar drug in China has been approved for marketing; Qilu 2 heavy-duty generic drugs have been approved: albumin paclitaxel for injection, tadalafil tablets; Huahai 4 + 7 "escitalopram oxalate tablets" the fourth one has passed the one-way evaluation We focus on the latest development of pharmaceutical research and development, and provide timely and accurate information reference for R & D personnel Today, Gilead Sciences announced that its descent, as a pre exposure prophylaxis (PREP) therapy to reduce the risk of HIV infection in men and transgender women, and biktarvy, which is used to treat patients with HIV for the first time, further confirmed their long-term effectiveness and safety in the extended phase of the three phase trial On November 6, 2019, the State Drug Administration updated the processing status of adalimumab (bat1406, trade name: gelleli) under baiaotai, and changed it to "approved - to be certified" This is not only the first adamumumab generic drug approved in China, but also the first drug approved for marketing by baiaotai On November 6, according to the new drug development monitoring database (CPM), the clinical application of Fosun first in class drug orin1001 was accepted by the State Food and Drug Administration (cxhl1900341, cxhl1900342), which was used to explore the treatment of recurrent, refractory and metastatic breast cancer On November 7, Jingfeng pharmaceutical announced that the supplementary application for consistency evaluation of gemcitabine hydrochloride for injection, a subsidiary of Hainan Jinrui pharmaceutical, was officially accepted by the drug evaluation center of the State Food and drug administration On November 6, Qilu pharmaceutical approved two heavy-duty generic drugs, paclitaxel for injection (albumin binding type) and tadalafil tablets Since they are registered in accordance with four categories, they are deemed to have passed the consistency evaluation after being approved Since then, these two heavy-duty varieties have passed the consistency evaluation in three domestic imitation enterprises On November 6, trelegy ellipta, a triple therapy of chronic obstructive pulmonary disease (COPD) developed by GSK, was approved by the State Food and drug administration Linezolid is a synthetic oxazolidinone antibiotic The original research enterprise is Pfizer It was first approved by the US FDA in 2000 It is used to treat infections caused by gram-positive cocci, including suspected or confirmed hospital acquired pneumonia (HAP), community acquired pneumonia (CAP), complex skin or soft tissue infection (SSTI) and vancomycin resistant Enterococcus (VRE) infection caused by MRSA On November 7, Huahai "escitalopram oxalate tablets" passed the consistency evaluation This is the fourth domestic enterprise that passed the consistency evaluation after Kelun, Jingwei and Dongting pharmaceutical industries.